Sugi Predict

Sugi Predict / Compounds / SCHEMBL8264176

SCHEMBL8264176

SCHEMBL8264176

Cc1cccc(N2CCC2)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADRB1 P08588 1/20 0.69
▸ KCNH2 Q12809 2/20 0.61
▸ MAPT P10636 3/20 0.56
▸ ALDH1A1 P00352 3/20 0.56
▸ RAB9A P51151 1/20 0.56
▸ NOTUM Q6P988 1/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ DHFR P00374 1/20 0.50
▸ HTR7 P34969 1/20 0.49
▸ ALOX5 P09917 2/20 0.49
▸ C1S P09871 1/20 0.48
▸ CA12 O43570 1/20 0.48
▸ CA1 P00915 1/20 0.48
▸ CA2 P00918 1/20 0.48
▸ CA9 Q16790 1/20 0.48
▸ PRMT6 Q96LA8 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ GAA P10253 1/20 0.47
▸ HPGD P15428 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27827352 0.98 ADRB1 (0.67) ADRB1KCNH2MAPTALDH1A1RAB9A
SCHEMBL12991 0.96 ADRB1 (0.69) ADRB1KCNH2MAPTALDH1A1RAB9A
SCHEMBL17281442 0.94 ADRB1 (0.67) ADRB1KCNH2MAPTALDH1A1RAB9A
SCHEMBL3307690 0.94 ADRB1 (0.67) ADRB1KCNH2MAPTALDH1A1RAB9A
Hydrochloric Acid SCHEMBL1803475 0.92 ADRB1 (0.65) ADRB1KCNH2MAPTALDH1A1RAB9A
SCHEMBL11103700 0.91 ADRB1 (0.74) ADRB1KCNH2MAPTALDH1A1RAB9A
SCHEMBL10373770 0.91 ADRB1 (0.74) ADRB1KCNH2MAPTALDH1A1RAB9A
SCHEMBL17144424 0.89 KCNH2 (0.59) ADRB1KCNH2MAPTALDH1A1RAB9A
SCHEMBL11096302 0.85 KCNH2 (0.73) ADRB1KCNH2MAPTALDH1A1RAB9A
SCHEMBL234093 0.84 ADRB1 (0.87) ADRB1KCNH2MAPTALDH1A1HTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116332929-A 3-amido-beta-carboline compound, preparation method and application thereof 中国科学院上海药物研究所 2023-06-27 — — CN disclosed
WO-2021155264-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 — — WO disclosed
US-20210032236-A1 NOVEL GLUTAMINASE INHIBITORS RHIZEN PHARMACEUTICALS AG (CH) 2021-02-04 — — US disclosed
EP-3092236-B1 NOVEL GLUTAMINASE INHIBITORS RHIZEN PHARMACEUTICALS S A (CH) 2020-08-26 — — EP disclosed
US-10611759-B2 Glutaminase inhibitors RHIZEN PHARMACEUTICALS SA (CH) 2020-04-07 — — US disclosed
US-20180057487-A1 NOVEL GLUTAMINASE INHIBITORS RHIZEN PHARMACEUTICALS AG (CH) 2018-03-01 — — US disclosed
US-9783533-B2 Glutaminase inhibitors RHIZEN PHARMACEUTICALS SA (CH) 2017-10-10 — — US disclosed
US-9783533-B2 Glutaminase inhibitors RHIZEN PHARMACEUTICALS SA (CH) 2017-10-10 — — US disclosed
US-20170281773-A1 BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2017-10-05 — — US disclosed
US-9675697-B2 BET bromodomain inhibitors and therapeutic methods using the same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2017-06-13 — — US disclosed
US-20160297761-A1 NOVEL INHIBITORS OF GLUTAMINASE RHIZEN PHARMACEUTICALS AG (CH) 2016-10-13 — — US disclosed
US-20160297761-A1 NOVEL INHIBITORS OF GLUTAMINASE RHIZEN PHARMACEUTICALS AG (CH) 2016-10-13 — — US disclosed
US-20160115169-A1 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS JANSSEN PHARMACEUTICA NV (BE) 2016-04-28 — — US disclosed
US-9102614-B2 Naphth-2-ylacetic acid derivatives to treat AIDS GILEAD SCIENCES, INC. (US) 2015-08-11 — — US disclosed
WO-2015101957-A2 NOVEL GLUTAMINASE INHIBITORS RHIZEN PHARMACEUTICALS SA (CH) 2015-07-09 — — WO disclosed
WO-2015101958-A2 NOVEL INHIBITORS OF GLUTAMINASE RHIZEN PHARMACEUTICALS SA (CH) 2015-07-09 — — WO disclosed
US-20130203727-A1 NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS GILEAD SCIENCES, INC. (US) 2013-08-08 — — US disclosed
EP-2177518-A1 Organic compounds Novartis AG (CH) 2010-04-21 — — EP disclosed
EP-1833816-B1 SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS NOVARTIS AG (CH) 2009-11-11 — — EP disclosed
WO-2006069788-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2006-07-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210032236-A1 NOVEL GLUTAMINASE INHIBITORS GLS, GLS2, GLUL ADRB1 4175/4885KCNH2 4401/4885MAPT 2866/4885
US-20180057487-A1 NOVEL GLUTAMINASE INHIBITORS GLS, GLS2, GLUL ADRB1 4175/4885KCNH2 4401/4885MAPT 2866/4885
US-20160115169-A1 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS GRM2, GRM5, GRM1 ADRB1 323/4885KCNH2 1222/4885MAPT 940/4885
US-20130203727-A1 NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS NFATC1, AADAT, ACAT1 ADRB1 2092/4885KCNH2 2759/4885MAPT 280/4885
US-20160297761-A1 NOVEL INHIBITORS OF GLUTAMINASE GLS, GLS2, GLUL ADRB1 4231/4885KCNH2 4390/4885MAPT 2817/4885
US-20170281773-A1 BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME BRD4, BRDT, BRD3 ADRB1 3674/4885KCNH2 4572/4885MAPT 2244/4885
US-10611759-B2 Glutaminase inhibitors GLS, GLS2, GLUL ADRB1 4236/4885KCNH2 4073/4885MAPT 2284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.